- Report
- August 2024
- 91 Pages
Europe
From €1421EUR$1,500USD£1,200GBP
- Report
- June 2020
- 753 Pages
Global
From €3127EUR$3,300USD£2,639GBP
- Report
- September 2023
- 93 Pages
Global
From €5638EUR$5,950USD£4,758GBP
- Report
- November 2023
- 175 Pages
Global
From €4738EUR$5,000USD£3,999GBP
From €2464EUR$2,600USD£2,079GBP
- Report
- July 2022
- 163 Pages
Global
From €4217EUR$4,450USD£3,559GBP
- Report
- July 2022
- 199 Pages
Global
From €4217EUR$4,450USD£3,559GBP
- Report
- September 2021
- 102 Pages
Global
From €4264EUR$4,500USD£3,599GBP
- Report
- February 2024
- 228 Pages
Global
From €7533EUR$7,950USD£6,358GBP
- Report
- November 2023
- 224 Pages
Global
From €7107EUR$7,500USD£5,998GBP
- Report
- May 2023
- 220 Pages
Global
From €2369EUR$2,500USD£1,999GBP
- Report
- April 2023
- 137 Pages
Global
From €7107EUR$7,500USD£5,998GBP
- Report
- May 2023
- 140 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- March 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,319GBP
- Report
- March 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,319GBP
- Report
- February 2024
- 120 Pages
Global
From €4501EUR$4,750USD£3,799GBP
- Report
- April 2023
- 112 Pages
Global
From €4501EUR$4,750USD£3,799GBP
- Report
- April 2023
- 110 Pages
Global
From €4501EUR$4,750USD£3,799GBP
- Report
- August 2022
- 115 Pages
Global
From €4501EUR$4,750USD£3,799GBP
- Report
- January 2022
- 121 Pages
Global
From €4501EUR$4,750USD£3,799GBP

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs.
Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection.
The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more